Pharmacologic management of diabetic nephropathy

Clinical Therapeutics

Volumn 24, Issue 11, 2002, Pages 1741-1756

  Vivian, Eva M ^a   Rubinstein, Gail Breen ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotension II receptor blockers; Calcium channel blockers; Diabetes mellitus; Diabetic nephropathy; Microvascular complications

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ALLOPURINOL; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTACID AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM CHANNEL BLOCKING AGENT; CAPSAICIN; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; ENALAPRIL; INDOMETACIN; IRBESARTAN; LISINOPRIL; LITHIUM; LOSARTAN; NONDIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; PROSTAGLANDIN; PROTEIN KINASE C; UNCLASSIFIED DRUG; VALSARTAN;

ACUTE KIDNEY FAILURE; AGRANULOCYTOSIS; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ATRIOVENTRICULAR BLOCK; BLOOD PRESSURE REGULATION; BRADYCARDIA; CLINICAL TRIAL; COUGHING; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DNA POLYMORPHISM; DRUG ANTAGONISM; DRUG COMBINATION; DRUG CONTRAINDICATION; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HEMODYNAMICS; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY DISEASE; MICROALBUMINURIA; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; POTASSIUM BLOOD LEVEL; PROTEIN INTAKE; PROTEIN URINE LEVEL; PROTEINURIA; RASH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINOPATHY; REVIEW; STATISTICAL ANALYSIS; URINALYSIS; VERTIGO;

EID: 0036861677     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)80076-5     Document Type: Article

References (57)

1. Ritz E, Orth SR. Nephropathy in patients with type 2 diabetes mellitus. N Engl J Med. 1999;341:1127-1133.
2. The USRDS and its products. United States renal data system. Am J Kidney Dis. 1998;32(2 Suppl 1):530-537.
3. American Diabetes Association Clinical Practice Recommendations 2002. Diabetic nephropathy. Diabetes Care. 2002;25 (Suppl 1):S85-S89.
4. Parving HH, Osterby R, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. 6th ed. Brenner and Rector's The Kidney. Philadelphia: WB Saunders; 1999:1831-1883.
5. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13-18.
6. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2446.
7. Wang SL, Head J, Stevens L, Fuller JH. Excess mortality and its relation to hypertension and proteinuria in diabetic patients. The World Health Organization multinational study of vascular disease in diabetes. Diabetes Care. 1996:19:305-312.
8. Larkins RG, Dunlop ME. The link between hyperglycaemia and diabetic nephropathy. Diabetologia. 1992;35:499-504.
9. Chowdhury TA, Dumar S, Barnett AH, Bain SC. Nephropathy in type 1 diabetes: The role of genetic factors. Diabetic Med. 1995;12:1059-1067.
10. Parring HH, Jacobsen P, Tarnow L, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: Observational follow up study. BMJ. 1996;313:591-594.
11. Cowie CC, Port FK, Wolfe RA, et al. Disparities in incidence of end stage renal disease according to race and type of diabetes. N Engl J Med. 1989;321:1074-1079.
12. Sawicki PT, Didjurgeit U, Muhlhauser I, et al. Smoking is associated with progression of diabetic nephropathy. Diabetes Care. 1994;17:126-131.
13. Keane WF. Lipids and the kidney. Kidney Int. 1994;46:910-920.
14. Mathiesen ER, Hommel E, Giese J, Parving HH. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ. 1991;303:81-87.
15. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care. 1997;20:1576-1581.
16. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
17. Ravid M, Savin H, Jutrin I, et al. Longterm stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med. 1993;118:577-581.
18. Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128(12 Pt 1):982-988.
19. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normo-albuminuria or microalbuminuria. The EUCLID Study Group. Lancet. 1997;349:1787-1792.
20. Viberti G, Mogensen CE, Groop LC, Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminutia Captopril Study Group. JAMA. 1994;271:275-279.
21. Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care. 1994;17:420-424.
22. Drug Facts and Comparisons. St. Louis, Mo: Lippincott, Williams & Wilkins, Inc; 2002.
23. Nawarskas JJ, Spinler SA. Update on the interaction between aspirin and angiotensin-converting enzyme inhibitors. Pharmacotherapy. 2000;20:698-710.
24. Andersen S, Tarnow L, Rossing P, et al. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int. 2000;57:601-606.
25. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
26. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
27. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation. 2002;106:672-678.
28. Loutzenhiser R, Epstein M, Horton C. Inhibition by diltiazem of pressure-induced afferent vasoconstriction in the isolated perfused rat kidney. Am J Cardiol. 1987;59:72A-75A.
29. Andersen S. Renal hemodynamic effects of calcium antagonists in rats with reduced renal mass. Hypertension. 1991;17:288-295.
30. Dworkin LD, Levin RI, Benstein JA, et al. Effects of nifedipine and enalapril on glomerular injury in rats with deoxycorticosterone-salt hypertension. Am J Physiol. 1990;259(4 Pt 2):F598-F604.
31. Bakris GL, Weir MR, DeQuattro V, McMahon FG. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283-1289.
32. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: Importance of therapeutic selection. Kidney Int. 1992;41:912-919.
33. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;112:707-708.
34. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med. 1993;153:973-980.
35. Smith AC, Toto R, Bakris GL. Differential effects of calcium blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int. 1998;54:889-896.
36. Abbott K, Smith A, Bakris GL. Effects of dihydropyridine calcium antagonists on albuminuria in patients with diabetes. J Clin Pharmacol. 1996;36:274-279.
37. Velussi M, Brocco E, Frigato F, et al. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes. 1996;45:216-222.
38. Zanetti-Elshater F, Pingitore R, Beretta-Piccoli C, et al. Calcium antagonists for treatment of diabetes-associated hypertension. Metabolic and renal effects of amlodipine. Am J Hypertens. 1994;7:36-45.
39. Holdaas H, Hartmann A, Lien MG, et al. Contrasting effects of lisinopril and nifedipine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med. 1991;229:163-170.
40. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria associated with diabetes mellitus. Ann Intern Med. 1990;113:987-988.
41. Crepaldi G, Carta Q, Deferrari G, et al. Effects of lisinopril and nifedipine on the progression to overt albuminuria in IDDM patients with incipient nephropathy and normal blood pressure. The Italian Microalbuminuria Study Group in IDDM. Diabetes Care. 1998;21:104-110.
42. Campbell PW. Research Highlight: Blood Pressure Drugs Protect Kidneys. National Institutes of Health Web site. Available at: http://www.ncrr.nih.gov/newspub/jan01rpt/Blood.asp. Accessed May 20, 2002.
43. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
44. Hebert LA, Falkenhain ME, Nahman NS Jr, et al. Combination ACE inhibitor and angiotensin II receptor antagonist therapy in diabetic nephropathy. Am J Nephrol. 1999;19:1-6.
45. Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ. 2000;321:1440-1444.
46. Rosman JB, ter Wee PM, Meijer S, et al. Prospective randomised trial of early dietary protein restriction in chronic renal failure. Lancet. 1984;2:1291-1296.
47. Ihle BU, Becker GJ, Whitworth JA, et al. The effect of protein restriction on the progression of renal insufficiency. N Engl J Med. 1989;321:1773-1777.
48. Locatelli F, Alberti D, Graziani G, et al. Prospective, randomised, multicentre trial of effect of protein restriction on progression of chronic renal insufficiency. Northern Italian Cooperative Study Group. Lancet. 1991;337:1299-1304.
49. Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994;330:877-884.
50. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
51. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study Group. Lancet. 1998;352:837-853.
52. American Diabetes Association Clinical Practice Recommendations 2002. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2002;25(Suppl 1):S5-S20.
53. Consensus Development Conference on the Treatment of Hypertension in Diabetes. Detection and management of lipid disorders in diabetes. Diabetes Care. 1996;19:S96-S113.
54. Moorhead JF. Lipids and progressive kidney disease. Kidney Int Suppl. 1991;31:S35-S40.
55. American Diabetes Association Clinical Practice Recommendations 2002. Management of dyslipidemia in adults with diabetes. Diabetes Care. 2002;25(Suppl 1):S74-S77.
56. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998;317:703-713.
57. American Diabetes Association Clinical Practice Recommendations 2002. Treatment of hypertension in adults with diabetes. Diabetes Care. 2002;25(Suppl 1):S71-S73.